SUNRAY-02: Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Condition: Non-Small Cell Lung Cancer
Sponsor: Eli Lilly and Company
Full Title
Protocol J3M-MC-JZQH: A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination with Standard of Care Immunotherapy in Participants with Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer
Study Treatment
KRAS G12C inhibitor Olomorasib in combination with standard systemic therapy.
Eligibility/Info
Eligible patients are diagnosed with a KRAS G12C mutant non-small cell lung cancer that is either stage II-IIIB, resected, and to be treated in the adjuvant setting or stage III, unresectable, and has been treated with platinum-based chemotherapy in combination with radiation.
Contact
For more information about this or any other study, please contact the NYCBS Research Department:
Email: ResearchRecruitment@nycancer.com
Telephone: 631-675-5075
HALO Messaging App: "Research Team"
Locations
Port Jefferson Station Medical Oncology
Riverhead Medical Oncology
Need More Information?
Our team is here to help answer your questions and guide you through your options.